Israel-based DreaMed scored another FDA clearance, expanding the availability of its AI-supported diabetes care platform to Type 2 patients.
The Advisor Pro Al Clinical Decision Support System helps healthcare providers manage the insulin needs of patients who use insulin pumps or injections and monitor their glucose levels using a continuous glucose monitor and/or blood glucose meters.
The...
Valerie Sullivan was named the next president of digital health company etectRx. This isn’t Sullivan’s first time working with the company. She has worked with the company in a consulting role for the last year. Her previous work experience includes serving as the president of InVentiv Patient Access Solutions and as the VP and general manager of the patient service center at Pear Therapeutics...
Interest in digital health is now sprouting up all over DC, from the president’s announcement of a new AI task force to FDA Commissioner’s shout out to digital health in his budget request.
In fact, the FDA is turning to developers in the digital health space to help solve some of the country’s most difficult problems. In May, the agency announced an innovation challenge aimed at tackling the...
The FDA has granted Isreal-based DreaMed Diabetes a de novo request for its artificial intelligence-powered software for providers managing patients with Type 1 diabetes.
“This is an innovation that can improve people’s lives and the FDA decision confirms what we believe is an important step in making a more meaningful connection between the healthcare provider and their type 1 diabetes patients...
Insulin dose tool gains CE Mark. DreaMed Diabetes has received a CE Mark for its Type 1-focused clinical decision support (CDS) platform, Advisor Pro. The tool’s algorithms process data from a number of connected diabetes management devices to provide a personalized insulin dosing treatment plan. The software achieved similar glycemic control when compared to medical experts during pilot studies...
During the month of July, MobiHealthNews reported on 16 digital health companies that raised venture funding. The deals total $149.3 million, which is lower on average when compared to other months this year so far but that's expected for the slower news cycle in the summer.
In the first half of 2016, MobiHealthNews tracked funding for digital health companies that totaled $1.27 billion, as we...
Israel-based DreaMed Diabetes announced this week that it has raised $3.3 million from Norma Investments, Russian businessman Roman Abramovich and one other unnamed angel.
The funds will mainly be used for further development of DreaMed’s Advisor, the company's decision support software that can be licensed and embedded into partners' diabetes management platforms.
For example, in February, the...
